Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Ultrasound reveals hidden stomach risks in semaglutide users

NCT ID NCT06292065

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study used bedside ultrasound to see if people taking semaglutide (Ozempic, Wegovy) have more food or liquid in their stomachs before surgery, despite fasting. Researchers compared 88 adults on semaglutide to those not taking it. The goal was to help anesthesiologists decide if it's safe to proceed with anesthesia or if changes are needed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide
What this could lead to
If successful, this could help doctors make safer anesthesia decisions for patients on semaglutide by better predicting stomach fullness.
What could go wrong
This is a small, completed observational study, not a treatment trial. Results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

88 people

The number who actually took part.

Started

Apr 2024

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria for the semaglutide cohort are: * Adults (\>=18 years old) * Semaglutide therapy for any indication (type 2 diabetes or weight loss) * Semaglutide therapy at any dose * Semaglutide therapy with any route of administration * Semaglutide therapy administered daily or weekly * Semaglutide therapy at any time since initiation * Elective surgery of any kind for which general anaesthesia was planned preoperatively * Adherence to current ASA recommendation regarding GLP-1-RA; i.e. holding semaglutide for 1 week if administered weekly or for 1 day if administered daily. * Adherence to current ESAIC fasting guidelines; i.e. \>2 hours for liquids and \>6 hours for solid foods. Inclusion criteria for the control cohort are: * Adults (\>=18 years old) * Elective surgery of any kind for which general anaesthesia was planned preoperatively * Adherence to current ESAIC fasting guidelines; i.e. \>2 hours for liquids and \>6 hours for solid foods Exclusion criteria for the semaglutide cohort are: * Semaglutide not held in accordance with current ASA recommendation, i.e. held either longer or shorter than recommended. * No adherence to current ESAIC fasting guideline * Presence of a contra-indication to gastric ultrasound; i.e. previous gastric surgery (e.g. partial gastrectomy, gastric bypass) or hiatal hernias. * Presence of comorbidities associated with delayed gastric emptying: scleroderma, systemic lupus erythematosus, hypothyroidism, Parkinson disease, cerebral palsy, and multiple sclerosis. * Inability to assume the right lateral decubitus position * Initial anaesthetic plan did not involve general anaesthesia, e.g. neuraxial or locoregional cases Exclusion criteria for the control cohort are: * Semaglutide or other GLP-1-RA therapy * No adherence to current ESAIC fasting guideline * Presence of a contra-indication to gastric ultrasound; i.e. previous gastric surgery (e.g. partial gastrectomy, gastric bypass) or hiatal hernias * Presence of comorbidities associated with delayed gastric emptying: scleroderma, systemic lupus erythematosus, hypothyroidism, Parkinson disease, cerebral palsy, and multiple sclerosis * Inability to assume the right lateral decubitus position * Initial anaesthetic plan does not involve general anaesthesia, e.g. locoregional cases

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastroparesis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Antwerp University Hospital

    Edegem, Antwerp, 2650, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.